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The Vesicular Acetylcholine Transporter Is Present
in Melanocytes and Keratinocytes in the Human
Epidermis
Souna M.A. Elwary1, Bhaven Chavan1 and Karin U. Schallreuter1,2
The human epidermis holds the full machinery for cholinergic signal transduction. However, the presence of
the vesicular transporter (vesicular acetylcholine (ACh) transporter (VAChT)) for both choline and ACh has
never been shown in this compartment. The results of this study confirm the presence of VAChT in cutaneous
nerves and in both epidermal melanocytes and keratinocytes as well as in their nuclei using immunofluor-
escence labelling in situ and in vitro, Western blot analysis of cellular and nuclear extracts and reverse
transcription-PCR. These results underline that ACh/choline transport in the non-neuronal epidermis is no
different from the neuronal pathway. However, the function of VAChT in the nucleus remains to be shown.
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INTRODUCTION
It has been demonstrated in situ and in vitro by several
investigators that the human epidermis holds the full capacity
for autocrine cholinergic signal transduction (Grando, 1997;
Grando and Horton, 1997; Grando et al., 2003). The
neurotransmitter acetylcholine (ACh) is synthesized in a
one-step reaction from choline and acetyl-coenzyme A by
ACh-O-transferase (EC 2.3.1.6, chAT) and hydrolysed by
acetylcholinesterase (EC 3.1.1.7). In cholinergic nerve end-
ings ACh is produced in the cytoplasm, then transported and
stored in synaptic vesicles (Israel, 1970). The vesicular ACh
transporter (VAChT) is responsible for the transport of ACh
and choline using a proton electrochemical gradient gener-
ated by a vacuolar type Hþ ATPase with the exchange of
two luminal protons for one cytoplasmic ACh or choline
(Parsons et al., 1993; Usdin et al., 1995; Bravo et al., 2004).
ACh transport requires a transmembrane pH gradient with an
internal pH between 5 and 6 causing the protonation of two
internal sites (Nguyen and Parsons, 1995).
Interestingly, the VAChT gene is located on chromosome
10 (10q11.2) which has been assigned also to the chAT gene
(Erickson et al., 1994). The VAChT gene is contained entirely
within the first intron of the chAT gene (Cervini et al., 1995).
VAChT and chAT are transcribed together in the same
direction. This unique nested gene arrangement allows a tight
coordinated regulation of both systems of ACh and choline
transport (Berrard et al., 1995; Usdin et al., 1995). Only
recently it was shown that the facilitation of VAChT
trafficking occurs through the trans-Golgi network-associated
AP-1 clathrin complex and the plasma membrane AP-2
complex (Kim and Hersh, 2004). Expression of this transpor-
ter was demonstrated in nerve fibers, at sweat glands and in
motor endplates (Haberberger et al., 2002). However, the
presence of VAChT was never documented in human
epidermal cells. Since these cells hold the entire cholinergic
machinery, it was tempting to look for the presence of this
important transporter.
RESULTS
In situ VAChT expression throughout the epidermis
Nowadays it is established that chAT is expressed in the
human epidermis (Grando et al., 1993) and that human
keratinocytes and melanocytes synthesize, secrete, and
degrade ACh (Grando et al., 1993). Since both chAT and
VAChT are sitting in the first intron of the same gene, it was
tempting to look for the expression of VAChT (Cervini et al.,
1995). For this purpose, we used full skin biopsies from
healthy controls and stained for VAChT protein expression
using immunofluorescence tetramethyl rhodamine isothio-
cyanate/FITC labelling. Moreover, the specificity of the
antibody was confirmed by utilizing a specific blocking
peptide.
As seen in Figure 1a VAChT is expressed throughout
the entire epidermis with the strongest positivity in the
stratum granulosum compared to basal and suprabasal
layers. VAChT is also expressed in nerves at the epidermal/
dermal junction (Figure 1e). This expression is significantly
abrogated in the presence of the blocking peptide indicating
that the antibody specifically detects VAChT (Figure 1b
and f).
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In order to identify whether melanocytes do express
VAChT in situ, we utilized double immunofluorescence with
VAChT and the melanocyte-specific gp100 (NKI/beteb)
protein (Figure 1c). The overlay shows that melanocytes fail
to express VAChT in situ (Figure 1d).
Epidermal keratinocytes and melanocytes express VAChT in
vitro
Both undifferentiated and differentiated keratinocytes express
VAChT in a perinuclear distribution, with some immuno-
positivity in the nucleus (Figure 2).
Under in vitro conditions VAChT is expressed throughout
the melanocyte including the nucleus and the dendrites
(Figure 3a). The expression of VAChT colocalizes strongly
with NKI/beteb in a subpopulation of cells while some other
cells do not colocalize (Figure 3b and c).
The presence of VAChT was confirmed in keratinocytes and
melanocytes as well as in their nuclei by Western blotting
In order to confirm VAChT expression as observed in situ and
in vitro in keratinocytes and in melanocytes, Western blotting
was performed in cellular and nuclear extracts of these cells
and in spinal cord extract (positive control). The extracts were
protected against possible proteolysis. The results showed
one band atB70 kDa in all extracts tested which was absent
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Figure 1. In situ immunofluorescence labelling demonstrates VAChT
expression in human epidermal keratinocytes, melanocytes and nerves.
(a) In situ expression. (b) Abrogation of immunoreactivity in the presence
of blocking peptide. (c) In situ expression of gp100 (NKI/beteb) in
melanocytes. (d) Overlay of the images showing no colocalization.
(e) Positive immunoreactivity in nerves at the epidermal/dermal junction (m).
(f) Abrogation of immunoreactivity in the presence of blocking peptide
(original magnification  400, bar¼ 50 mm).
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Figure 2. In vitro expression of VAChT in epidermal keratinocytes. (a–d)
Undifferentiated keratinocytes. (a) VAChT. (b) VAChT in the presence of
blocking peptide. (c) CK5 expression confirming undifferentiated cells.
(d) VAChT and 40,6-diamino-phenylindole colocalization showing little
nuclear VAChT expression (original magnification  400, bar¼ 50 mm).
(e–h) Differentiated keratinocytes. (e) VAChT. (f) VAChT in the presence
of blocking peptide. (g) CK10 expression confirming differentiated cells.
(h) VAChT and 40,6-diamino-phenylindole colocalization suggesting nuclear
VAChT expression. The inset shows a close up of a single cell (original
magnification  400, bar¼ 50 mm).
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when the extracts were blocked before analysis (Figure 4a
and b). The result is in agreement with the published size of
VAChT (Varoqui and Erickson, 1996; Tayebati et al., 2002;
Oda et al., 2004). Based on these data we can conclude that
epidermal melanocytes and keratinocyte and their nuclei
express VAChT.
Presence of mRNA for VAChT in epidermal keratinocytes and
melanocytes
To further support the evidence for VAChT in keratinocytes
and melanocytes we employed reverse transcription-PCR. As
positive control we used peripheral lymphocytes (Tayebati
et al., 2002). The product was calculated based on the
GenBank accession number: U10554 and the product size
was predicted as 310 bp. The band corresponded to the
expected size of VAChT in lymphocytes and in both
melanocytes and keratinocytes (Figure 5). The PCR product
confirmed the correct sequence (data not shown).
DISCUSSION
The presence of VAChT expression in epidermal keratino-
cytes and melanocytes has never been explored previously.
Our findings show that this transporter is present with
homogeneous distribution throughout the epidermis. The
positivity of this expression was increased upon differentia-
tion as seen both in situ (Figure 1a) and in vitro (Figure 2a–d
and e–h). This result would be in agreement with higher ACh
levels in the suprabasal layers supporting that more ACh is
needed towards differentiation (Grando et al., 1993).
Even though the in situ results showed no detectable
expression of VAChT in melanocytes (Figure 1d), the
expression was very pronounced in a subpopulation of
melanocytes cultured under in vitro conditions (Figure 3a
and c). The presence of subpopulations deserves further
investigation. Western blotting analysis confirmed the pre-
sence of VAChT in both keratinocytes and melanocytes as
well as in their nuclei. The role for the transporter in the
nucleus has to be established. Transcription of the important
transporter was confirmed by reverse transcription-PCR
showing the presence of its mRNA in both keratinocytes
and melanocytes.
Since, VAChT is present at the periphery of melanocytes,
keeping ACh close to the myosin Va fibers, which reside in
the same area, we propose that ACh transport by VAChT may
facilitate transfer of melanosomes. This hypothesis would be
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Figure 3. In vitro expression of VAChT in epidermal melanocytes. (a) VAChT. (b) Expression of gp100 (NKI/beteb) in melanocytes. (c) Overlay of the images
showing colocalization. The inset shows VAChT and 40,6-diamino-phenylindole colocalization indicating the presence of VAChT in the nucleus (original
magnification  400, bar¼ 50 mm).
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Figure 4. Immunoblotting confirms the presence of VAChT in epidermal
keratinocytes, melanocytes, and in the nuclei of both cell types together with
positive control (spinal cord extract). (a) Western blot analysis: VAChT is
expressed in total, cytosolic and nuclear extracts of melanocytes and
keratinocytes and in spinal cord extract (positive control) with one band at
approx. 70 kDa. (Lane 1: MW Ladder, lane 2: total keratinocyte cells, lane 3:
cytosolic keratinocyte cells, lane 4: nuclear keratinocyte cells, lane 5: total
MC, lane 6: cytosolic MC, lane 7: nuclear MC, lanes 8 and 9: spinal cord
extract (10 ml), and lane 10 spinal cord extract (2 ml). (b) Western blot analysis
after pre-absorption with the specific VAChT-blocking peptide.
bp lad Neg KC MC Lymph
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Figure 5. Reverse transcription-PCR confirms the presence of VAChT mRNA
in epidermal melanocytes and keratinocytes. The 310 bp band is in
agreement with the expected size. Lymphocytes served as positive control.
VAChT mRNA is expressed in MC and keratinocyte cells. The product was
confirmed by sequence analysis (data not shown).
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in agreement with dispersion, pigment redistribution melano-
somal movement by ACh as observed in the skin of lower
vertebrates (Hayashi and Fujii, 1994; Ovais, 1994; Ali et al.,
1995).
In summary, we here provide early evidence for the
presence of VAChT in human epidermal melanocytes and
keratinocytes in situ and in vitro. Our results add this ACh/
choline transporter as an important missing piece to the well-
documented cholinergic signal transduction system in the
epidermal compartment.
MATERIALS AND METHODS
Full skin biopsies from Caucasian healthy controls (skin
phototype III, Fitzpatrick classification)
Punch biopsies (3 mm) were obtained under local anesthesia and
embedded in OCTTM medium (Sakura, Newbury, Bershire, UK)
followed by snap freezing in liquid nitrogen. The samples were
stored at 801C until required or cut into 5–7 mm thick sections using
a cryostat (Leica CM 1800, Wetzlar, Germany), directly affixed onto
prepared poly-L-lysine-coated slides (SIGMA, Poole, UK), and stored
at 801C until further use. The local ethics committee approved this
study. The study was conducted according to the Declaration of
Helsinki Principles.
Human epidermal melanocytes and keratinocytes cell cultures
Epidermal melanocytes were grown from epidermal suction blister
roof tissue in MCDB 153 medium using the method of Pittelkow and
Shipley (1989).
Keratinocytes were established from breast reduction skin or
epidermal suction blister roofs in MCDB 153 medium using the
method of Wille et al. (1984). Suction blisters were obtained from
the distal inner forearm using the method of Kiistala (1968).
Immunofluorescence labelling of full skin sections, cultured
melanocytes, and keratinocytes
Cryo-cut sections (5–7 mm) of normal human full skin biopsies and
slides containing keratinocyte or melanocyte cell (MC) cultures were
fixed in acetone for 15 minutes at 201C. Sections/cells were
blocked with 10% normal serum for 90 minutes followed by a 3
wash in phosphate-buffered saline. Subsequently, sections/cells
were incubated overnight at 41C with the primary antibody(s),
washed 3 in phosphate-buffered saline followed by incubation for
90 minutes at room temperature with FITC/tetramethyl rhodamine
isothiocyanate-labelled secondary antibody(s). Immunoreactivity
was viewed and captured using a Leica DM-IRB inverted micro-
scope (Leica Microsystems, Wetzlar, Germany) coupled to a digital
camera together with Neotech ‘‘Image Grabber PCI’’ imaging
software. In order to compare intensity of protein expression,
staining was carried out in one set. Sources and dilutions of the
antibodies used are summarized in Table 1.
Western blot analysis
In order to confirm the presence of the VAChT protein observed in
situ and in vitro, we used Western blot analysis with specific
blocking peptide as negative controls. Table 2 summarizes the
antibody, blocking peptide, and dilutions used for this purpose.
Table 1. Sources and dilutions of primary and secondary antibodies
Ab name/clone type Host Antigen Dilution Antibody source
Melanoma-associated Ag
premelanosomal Ab
gp100, clone NKI/beteb
Mouse 100 kDa, 7 kDa 1:20 in all sources Monosan, Bradsure
Biologicals Ltd,
Loughborough, UK
FITC-conjugated anti-mouse
IgG (for double labelling
of MC)
Donkey Mouse IgG 1:100 in all sources Jackson Immunoresearch
Laboratories, West Grove, PA
Anti-VAChT, polyclonal Goat Synthetic peptide from cloned
rat VAChT carboxy terminal
In situ
1:500
KC 1:100
MC 1:5
CHEMICON International,
Temecula, CA
VAChT-blocking peptide
for anti-VAChT
Synthetic peptide Synthetic peptide In situ
1:500
KC 1:100
MC 1:5
CHEMICON International,
Temecula, CA
TRITC-conjugated
anti-goat IgG
Donkey Goat IgG 1:100 in all sources Jackson Immunoresearch
Laboratories, PA
Anti-cytokeratin 5,
monoclonal
Mouse Prokaryotic recombinant protein
corresponding to 103 amino-acid
portion of the C-terminal region of the
cytokeratin 5 molecule (human)
KC 1:150 Abcam Ltd, Cambridge, UK
Anti-cytokeratin 10,
monoclonal
Mouse Tissue/cell preparation (human).
Cytoskelaton preparation (extracted from
human epidermis by detergent/light salt
extraction)
KC 1:150 Abcam Ltd, Cambridge, UK
FITC emits a green fluorescence (lex 495 nm/lem 515 nm). Tetramethyl rhodamine isothiocyanate emits a red fluorescence (lex 575 nm/lem 600 nm).
1882 Journal of Investigative Dermatology (2006), Volume 126
SMA Elwary et al.
The Vesicular Acetylcholine Transporter
Preparation of total keratinocyte and melanocyte cellular
lysates
The flasks are rinsed 2 with ice-cold phosphate-buffered saline
keeping the flask on ice at all times followed by the addition of 2 ml
cold phosphate-buffered saline/EDTA solution and 10 ml Pi (protease
inhibitor) (SIGMA, poole, UK). Cells were harvested by gentle
scraping followed by centrifugation for 5 minutes at 750 g. The
pellet is resuspended in 150 ml sterile distilled water followed by 6
repeat freezing-thawing cycles and a final centrifugation for
5 minutes at 750 g. The determination of the protein concentration
was based on the OD280 nm measurement using the method of Kalb
and Bernlohr (1977). The samples were mixed with sample buffer
and used for SDS-PAGE electrophoresis.
Preparation of cytoplasmic and nuclear keratinocyte cell and
MC extracts
Cytoplasmic and nuclear extracts were obtained by following the
manufacturer’s instructions (Active Motif, Rixensart, Belgium).
Briefly, cells were cultured until near confluency followed by
treatment with phosphate-buffered saline/phosphatase inhibitors and
then gently scraped and pelleted. The pellet was resuspended in
hypotonic buffer and the obtained supernatant contained the
cytoplasmic extract. The remaining pellet was resuspended in lysis
buffer and the supernatant provided the nuclear fraction. In order to
ensure nuclear purity, samples were tested for cross-contamination
via the lactate dehydrogenase assay (Stockland and San Clemente,
1968).
Peripheral blood lymphocyte preparation
Peripheral blood lymphocytes were obtained from healthy volun-
teers after written and signed consent. They were prepared using
LymphoprepTM (Axis-shield poc AS, Oslo, Norway).
Total RNA preparation
Total RNA was isolated from epidermal primary keratinocyte and
MC cultures as well as lymphocyte preparation using TRI
REAGENTTM (SIGMA, Poole, UK) following manufacturers instruc-
tions. cDNA was synthesized using the reverse transcription system
(Promega, Southampton, UK). The reaction mix contained about
1mg total RNA and 500 pmol of oligo dT primer in a final volume of
20 ml. The negative control contained RNA but no reverse
transcriptase.
Reverse transcription-PCR for the detection of VAChT-mRNA
PCR amplification of 2ml cDNA was used in a final volume of 50 ml
containing 10 PCR reaction buffer (200 mM Tris-HCl, pH 8.4,
500 mM KCl; Life Technologies, Paisley, UK), 1mmole dNTP (10 mM
each of the four nucleotides; Promega, Southampton, UK),
100 nmole MgCl2 (Life Technologies, Paisley, UK), 1 pmole of each
primer and 2.5 U of recombinant Taq DNA polymerase (Life
Technologies, Paisley, UK). The mixture was incubated initially for
3 minutes at 941C followed by 40 cycles with 1 minute at 941C,
1 minute at 561C (reduced by 0.11C per cycle), and 30 seconds at
721C. The primer pair (forward: 50-ACTACTACACCCGCAGCTAG-30
and reverse: 50-ACAGATGCAGGCTCTACACA-30) was designed
using the mRNA sequence of human VAChT (GenBank accession
number: U10554). As positive control we utilized mRNA from
peripheral blood lymphocytes.
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